FBXW11 and NFKBIA

Number of citations of the paper that reports this interaction (PubMedID 10644755)
49

Data Source:
HPRD (in vivo, in vitro)

		FBXW11	NFKBIA
Description		F-box and WD repeat domain containing 11	NFKB inhibitor alpha
Image		No pdb structure
GO Annotations	Cellular Component	Ubiquitin Ligase Complex Nucleus Centrosome Cytosol SCF Ubiquitin Ligase Complex	Nucleus Nucleoplasm Cytoplasm Cytosol Plasma Membrane I-kappaB/NF-kappaB Complex
	Molecular Function	Ubiquitin-protein Transferase Activity Protein Binding Protein Dimerization Activity Ubiquitin Protein Ligase Activity	Protein Binding Transcription Factor Binding Nuclear Localization Sequence Binding Enzyme Binding Ubiquitin Protein Ligase Binding Identical Protein Binding NF-kappaB Binding
	Biological Process	G2/M Transition Of Mitotic Cell Cycle Protein Polyubiquitination Stimulatory C-type Lectin Receptor Signaling Pathway Protein Dephosphorylation Ubiquitin-dependent Protein Catabolic Process Viral Process Wnt Signaling Pathway Protein Ubiquitination SCF-dependent Proteasomal Ubiquitin-dependent Protein Catabolic Process Protein Destabilization NIK/NF-kappaB Signaling Fc-epsilon Receptor Signaling Pathway Positive Regulation Of Circadian Rhythm Proteasome-mediated Ubiquitin-dependent Protein Catabolic Process Post-translational Protein Modification Positive Regulation Of Proteolysis Negative Regulation Of Transcription, DNA-templated Positive Regulation Of Transcription, DNA-templated Rhythmic Process T Cell Receptor Signaling Pathway Stress-activated MAPK Cascade Interleukin-1-mediated Signaling Pathway Negative Regulation Of NIK/NF-kappaB Signaling	Protein Import Into Nucleus Apoptotic Process I-kappaB Kinase/NF-kappaB Signaling Cytoplasmic Sequestering Of NF-kappaB Negative Regulation Of Macrophage Derived Foam Cell Differentiation Positive Regulation Of Cholesterol Efflux Negative Regulation Of Lipid Storage Viral Process Protein Deubiquitination Lipopolysaccharide-mediated Signaling Pathway Negative Regulation Of NF-kappaB Transcription Factor Activity Positive Regulation Of Cellular Protein Metabolic Process Response To Muramyl Dipeptide Tumor Necrosis Factor-mediated Signaling Pathway Toll-like Receptor 4 Signaling Pathway Response To Muscle Stretch Regulation Of Cell Proliferation Cytoplasmic Sequestering Of Transcription Factor Negative Regulation Of Apoptotic Process Response To Exogenous DsRNA Negative Regulation Of DNA Binding Negative Regulation Of Myeloid Cell Differentiation Negative Regulation Of Notch Signaling Pathway Positive Regulation Of Transcription By RNA Polymerase II Positive Regulation Of Inflammatory Response Cellular Response To Cold Nucleotide-binding Oligomerization Domain Containing 1 Signaling Pathway Nucleotide-binding Oligomerization Domain Containing 2 Signaling Pathway Interleukin-1-mediated Signaling Pathway Regulation Of NIK/NF-kappaB Signaling
Pathways		Activation of NF-kappaB in B cells Downstream TCR signaling Regulation of PLK1 Activity at G2/M Transition FCERI mediated NF-kB activation Dectin-1 mediated noncanonical NF-kB signaling CLEC7A (Dectin-1) signaling NIK - noncanonical NF-kB signaling MAP3K8 (TPL2)-dependent MAPK1/3 activation Neddylation Antigen processing: Ubiquitination & Proteasome degradation	Activation of NF-kappaB in B cells RIP-mediated NFkB activation via ZBP1 Downstream TCR signaling NF-kB is activated and signals survival FCERI mediated NF-kB activation TAK1 activates NFkB by phosphorylation and activation of IKKs complex SUMOylation of immune response proteins IkBA variant leads to EDA-ID CLEC7A (Dectin-1) signaling Ub-specific processing proteases Interleukin-1 signaling TRAF6 mediated NF-kB activation
Drugs			Acetylsalicylic acid Astaxanthin
Diseases			Ectodermal dysplasia associated immunodeficiency (EDA-ID), including the following two diseases: NF-kappa-B essential modulator (NEMO) defect; Inhibitor of kappa-B (I-kappa-B) defect Hodgkin lymphoma
GWAS		Height ( 28552196 20881960 25282103 25429064 23563607 31562340) Waist circumference adjusted for BMI (adjusted for smoking behaviour) ( 28443625) Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction) ( 28448500) Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction) ( 28443625) Waist circumference adjusted for BMI in active individuals ( 28448500) Waist circumference adjusted for BMI in non-smokers ( 28443625) Waist circumference adjusted for body mass index ( 25673412 28448500)	Asthma ( 30929738) Asthma (childhood onset) ( 30929738) Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) ( 26974007) Creatine kinase levels ( 29403010) Eczema ( 31361310) Hip circumference adjusted for BMI ( 25673412) Inflammatory skin disease ( 25574825) Lymphocyte counts ( 27863252) Psoriasis ( 25854761 25903422 20953189 20953190 25574825 23143594) Psoriasis vulgaris ( 26626624) Pulse pressure ( 27841878 30578418) Systolic blood pressure ( 27841878 28739976 30578418)
Interacting Genes		23 interacting genes: BHLHE41 BTRC CDC25A CSNK1E CUL1 DAPK1 GLI2 GSK3B IFNAR1 KDR MCL1 NFKB1 NFKBIA PPP1CC PPP2R1B PPP2R5E PRKACA PRLR TBC1D4 TRIM21 UBE2D3 WEE1 ZNF281	87 interacting genes: ABL1 ARRB1 ARRB2 ATF4 AURKA BARD1 BTRC CAPN1 CAPN2 CD7 CDC34 CHUK COMMD1 COPS8 CSNK2A1 CUL1 DNAJA3 DYNLL1 EIF2AK2 ELOC ELP1 FBXW11 G3BP2 HDAC1 HDAC3 HNRNPA1 HOXA9 HOXB7 HSPB1 IKBKB IKBKE IKBKG IKZF4 ITPK1 JAK2 LCK LYL1 MAP3K1 MAP3K14 MAP3K2 MAP3K3 MAP3K7 MCM5 MCM7 MED19 NCOR2 NEDD9 NFKB1 NFKB2 NFKBIB NKIRAS1 NKIRAS2 PIK3R1 PIR POLR2C POM121 PRKCA PRKCI PSMA2 PTPN1 PTPN13 REL RELA RNF115 RPS6KA1 RPS6KA3 RWDD3 SKP1 SLC25A4 SLC25A5 SRC ST7 SUMO1 SUMO4 TBK1 TNF TNFSF11 TP53 TUBA1B UBE2D1 UBE2D2 UBE2D3 UBE2E3 UBE2I UBE2L3 VCP ZNF212
Entrez ID		23291	4792
HPRD ID		07294	01235
Ensembl ID		ENSG00000072803	ENSG00000100906
Uniprot IDs		B4DH70 Q9UKB1	P25963
PDB IDs			1IKN 1NFI
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?